## **NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS**

## Request for Insured Coverage of Mepolizumab (Nucala) for Chronic Rhinosinusitis

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
INITIAL REQUEST			
·			
For the treatment of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who meet <u>all</u> of the following criteria:			
1. ☐ Endoscopically or CT-documented bilateral nasal polyps			
2. Undergone at least 1 prior surgical intervention for nasal polyps or have a contraindication to surgery			
3.  Tolerant and able to continue use of inhaled nasal corticosteroids but have refractory symptoms despite use of inhaled corticosteroids for 3 months at maximally tolerated doses.			
Inhaled Nasal Corticosteroid: Dose: Duration:			
4. Please provide one of the following scores:			
☐ Baseline Sino-nasal Outcome Test (Si	NOT-22): Da	ate:	<u>OR</u>
☐ Baseline endoscopic Nasal Polyp Scor	re (NPS): Da	ate:	
RENEWAL REQUEST			
Requests for renewal must exhibit a clinically meaningful response defined as one of the following:			
☐ A decrease of 8.9 points or greater on the Sino-nasal Outcome Test (SNOT-22) relative to their baseline score			
SNOT-22:	SNOT-22: Date: <u>OR</u>		
☐ A decrease of 1 point or greater on the endoscopic Nasal Polyp Score (NPS) relative to their baseline score.			
NPS: Date:			
PRESCRIBER NAME & ADDRESS:			
_			
If you need accietones places contain		BER SIGNATURE DA	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs P.O. Box 500, Halifax, NS B3J 2S1

Fax: (902) 496-4440

